INTERCEPT Platelets: Abstracts

2010 ABSTRACTS

XXXIst International Congress of the International Society of Blood Transfusion (ISBT)
June 26 - 1, 2010 | Berlin, Germany

1. Nicolas Malvaux, Paul Courrier, Michel Collart. Validation of Pooled Buffy Coat Platelet Components Suspended in a Mixture of Plasma and SSP+ Treated with INTERCEPT™ Pathogen Inactivation at Center for Transfusion Services (CTS) in Luxembourg. Vox Sanguinis 2010;99 (Suppl. 1), 253
   [Poster PDF]
   
   
2. Arzu Agildere, Sabine Reppke, Udo Schäfer et al. Implementation of 5 Buffy Coat Pooled Platelet Units Treated With INTERCEPT Blood System: Experience at the DRK Blutspendedienst in Baden-Baden. Vox Sanguinis 2010;99 (Suppl. 1), 257
   
   
3. Bettina Lizardo, Kerstin Braukmann, Inge Lüdtke et al. Implementation of 5 Buffy Coat Pooled Platelet Components Treated with the INTERCEPT Blood System™: Experience in German Red Cross Blood Donation Service Nord. Vox Sanguinis 2010;99 (Suppl. 1), 258
   [Poster PDF]
   
   
4. Maria Jessen, Igor Steinle, Maren Braun et al. Validation of Apheresis Platelet Components Treated with INTERCEPT™ Pathogen Inactivation at the Institute Schleswig German Red Cross North. Vox Sanguinis 2010;99 (Suppl. 1), 258
   
   
5. B Baumann-Baretti, G Jaster, B Brys et al. Production of Two Therapeutic Platelet Components Pathogen Inactivated with a Single INTERCEPT Dual Storage (DS) Processing Set from Double- and Triple Dose Apheresis by MCS+® and Trima 5.1 Accel®. Vox Sanguinis 2010;99 (Suppl. 1), 248
   
   
6. Mohammad R Abedi, Marie-Louise Wiiand, Ann-Charlotte Doverud et al. Apheresis Collection of Double and Triple Platelet Doses Pathogen Inactivated with INTERCEPT Blood System™: Manufacturing and Clinical Outcome. Vox Sanguinis 2010;99 (Suppl. 1), 242
   
   
7. Olivier Garraud, Fabrice Cognasse, Patricia Chavarin et al. Validation of INTERCEPT™ Pathogen Inactivation Process for Platelet Components Suspended in a Mixture of Plasma and SSP+ at a Regional Center (EFS Auvergne Loire In France). Vox Sanguinis 2010;99 (Suppl. 1), 253
   
   
8. F Ipsevich, A De Rosa, M Miceli et al. Use of Pathogen-Inactivated Apheresis and Buffy-Coat Pool Platelet Concentrates: Evaluation Program of Transfusional Quality and Efficacy. Vox Sanguinis 2010;99 (Suppl. 1), 257
   
   
9. JC Osselaer, L Defoin, C Doyen et al. INTERCEPT for Pathogen Inactivation (PI) in Platelet Concentrates (PC) Effectively Prevents Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD). Vox Sanguinis 2010;99 (Suppl. 1), 428
   [Poster PDF]
   
   
10. Folke Knutson, Karin Lejskog and Helena Löf. A Feasibility Study with the TACSI™ Device Producing 2 Doses of Platelets Stored for 7 Days with the Use of One INTERCEPT™ Pathogen Inactivation Kit. Vox Sanguinis 2010;99 (Suppl. 1), 202
    
    
11. Michael Müller-Steinhardt ,Karin Janetzko. Evaluation of Apheresis Platelet Concentrates Treated with INTERCEPT™ Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 252
    
    
12. JC Osselaer, B De Coene, MC Thonet et al. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components Stored for More Than 5 Days: A Nine Year Hemovigilance Survey. Vox Sanguinis 2010;99 (Suppl. 1), 433
    [Poster PDF]
    
    
13. Hervé Isola, Daniel Kientz, Marie-Louise Wiesel et al. The Use Of TACSI® System: Effect Of Automation On Routine Production Of Pooled Platelet Concentrates For Pathogen Inactivation At The EFS-Alsace. Vox Sanguinis 2010;99 (Suppl. 1), 212

12th International Haemovigilance Seminar
February 17 - 19, 2010 | Dubrovnik, Croatia

1. JP Cazenave, D Kientz, I Mendel, H Isola, C Waller. Hemovigilance Surveillance Of Platelet Components Prepared With Pathogen Inactivation Treatment During a Three Year Period.
   [Abstract PDF] [Poster PDF]
   
   
2. D Domanovic, A Milojkovic, M Cukjati, J Irsch, L Lin. Hemovigilance of Transfusions with Platelet Treated with INTERCEPT Blood System Using an Active Hemovigilance Program - Data from Slovenia.
   [Abstract PDF]
   
   
3. F Knutson, H Lof. HV at a University Hospital After Transfusions of Platelets Pathogen Inactivated with the INTERCEPT Technology.
   [Abstract PDF]
   
   
4. JC Osselaer, JP Cazenave, W Liu, A Elliot, W Reed, L Lin, L Corash. An Active Hemovigilance Program to Assess the Safety Outcome for 18,641 Platelet Components Tranfused in Multiple European Clinical Sites.
   [Abstract PDF]
   
   
5. JC Osselaer, B De Coene, MC Thonet, C Corlier, J Jamart, C Doyen. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components: A Six-year Hemovigilance Survey.
   [Poster PDF]

2009 ABSTRACTS

Jump to conference:
October - AABB
September - DGTI
June - SETS, EHA
March - ISBT

2009 AABB Annual Meeting & TXPO
October 24 - 27, 2009 | New Orleans, USA
[back to top]

1. L Sawyer, R Mababangloob, N Patel, J Kinsey, A Sampson-Johannes, D Hanson. Pathogen Inactivation Achieved with Amotosalen and UVA in Platelets Suspended in Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol. Transfusion 2009; 49(suppl 1):95A
   [Poster PDF]
   
   
2. RE Agliastro, G DeFrancisci, M Diquattro, R Bonaccorso, M Tagliavia, M Marcatti, B Palma. Should the Use of Pathogen Inactivated Platelet Concentrates Be Extended to 7 Days? In Vitro Study on the Quality of Platelets at 3, 5 and 7 Days. Transfusion 2009; 49(suppl 1):96A
   
   
3. D P Brilhante, S Rodrigues, M Santos, L Castro. Platelet Components Treated with Pathogen Inactivation: Clinical Outcomes of the First Single Center Observational Study in Lisbon, Portugal. Transfusion 2009; 49(suppl 1):97A
   
   
4. L Defoin, L Bouchat, M Goffaux, S Vanden Bossche, P Paternostre, M Vandendaele, M van Hooydonk, JC Osselear. Transfusion Efficacy Determined by the CCI at 24 Hours Is Not Influenced by the Collected Platelet Yield with Amicus®. Transfusion 2009; 49(suppl 1):162A
   
   
5. E Girona-Llobera, TM Jimenez-Marco, M Sedeño, J Muncunill. The Impact of the Platelet Pathogen Inactivation Technology on the Platelet Inventory Management. Transfusion 2009; 49(suppl 1):266A
   

42nd Annual Congress of the German Society for Transfusion Medicine and Immunohaematology (DGTI)
September 15 - 18, 2009 | Rostock, Germany
[back to top]

1. M Deane, P Rivera, L Sawyer. INTERCEPT Platelets Treated and Stored in SSP+ Meet Council of Europe Standards for In Vitro function After 7 Days of Storage. Transfus Med Hemother 2009;36(suppl 1):1-62
   
   
2. R Henschler, M Wiesneth, H.-U Pfeiffer, M Muller, S Andresen, A Kramer, J Irsch, L Lin, L Corash, H Schrezenmeier, E Seifried. Double-Dose Platelet Concentrates Prepared from Pools of 7 or 6 Buffy Coats for Pathogen-Inactivation with the INTERCEPT System. Transfus Med Hemother 2009;36(suppl 1):1-62

Congreso Nacional de la Sociedad Espanola de Transfusion Sanguinea (SETS)
June 11 - 13 | Tarragona, Spain
[back to top]

1. E Girona-Llobera, MT Jiménez-Marco, M Sedeño, N Serra, J Muncunill. Implantación en un centro de transfusión del sistema INTERCEPT de inactivatión de patógenos de componentes plaquetarios.

14th Annual Congress of the European Hematology Association (EHA)
June 4 - 7, 2009 | Berlin, Germany
[back to top]

1. P Cazenave, ML Wiesel, I Mendel, A Faradji, S Mangin, B Perricard, D Kientz. Transfusion of Platelet Components Prepared with Photochemical Pathogen Inactivation for Support of Severe Glanzmann Thrombasthenia During Surgical Procedures.
   [Poster PDF]
   
   
2. JC Osselaer, JP Cazenave, P Rasongles, F Knutson, L Lin and L Corash on behalf of the INTERCEPT Platelet Hemovigilance Study Group. An Active Hemovigilance Program to Characterize the Safety Profile of 16,631 Platelet Components Prepared with Photochemical Pathogen Inactivation Treatment Transfused In Routine Clinical Practice.
   

XIXth Regional Congress International Society of Blood Transfusion (ISBT)
March 21 – 25, 2009 | Cairo, Egypt
[back to top]

1. JC Osselaer, C Doyen, L. Defoin, S. Vandenbossche, C Debry, et al. A Two-Year Experience of Transfusing Platelet Components Prepared with INTERCEPT Pathogen Inactivation System and Stored for Up to 7 Days.Vox Sanguin 2009;96(Suppl 1):61-62.
   
   
2. R Al-Radwan, R Al-Abdulrazzak, S Al-Shatti, G Boland, G Ashkanani, et al. Standardization of Platelet Components Treated with INTERCEPT Pathogen Inactivation at Kuwait Central Blood Bank. Vox Sanquin 2009;96(Suppl 1):219.
   [Poster PDF]
   
   
3. L Defoin, S Vandenbossche, M van Hooydonk, P Paternostre, A Caucheteux, L Lin and JC Osselaer. Evaluation of in vitro Platelet Properties of Apheresis Platelets Collected in 100% Plasma Treated with INTERCEPT Blood System and Stored for Up to Nine Days. Vox Sanquin 2009;96(Suppl 1):221-222.
   [Poster PDF]
   
   
4. L Lin, M Deane, P Rivera, P Carmichael and L Sawyer. Treatment of Double Dose Platelet Components with the INTERCEPT Blood System and Subsequent Storage in Two Containers.
   Vox Sanquin 2009;96(Suppl 1):226-227.
   [Poster PDF]
   
   
5. L Sawyer, S Higgs, K Tsetsarkin, D Vanlandingham, R Johnson. Inactivation of Transfusion-Transmitted Vector Borne Pathogens. Vox Sanquin 2009;96(Suppl 1):233-234.
   [Poster PDF]

2008 ABSTRACTS
Jump to conference:
October - AABB
September - DGTI
June - ISBT
May - SETS

American Association of Blood Banks Annual Meeting (AABB)
October 4-7, 2008 | Montréal, Canada
[back to top]

1. JC Osselaer, C Doyen, L Defoin et al. Response to Transfusion of 6- and 7-Day-Old Platelet Components Prepared with INTERCEPT Pathogen Inactivation System.Transfusion 2008;48 (S1);20A-21A
   
   
2. L Corash, J-S Lin, J Eiden. Serious Pulmonary Adverse Events & Acute Lung Injury Following Repeated Platelet Transfusions.Transfusion 2008;48 (S1);28A
   
   
3. JP Cazenave, C Waller, I Mendel et al. Impact of Photochemical Treatment of Platelet Components (INTERCEPT ™) on Platelet and RBC Component Use by Hematology-Oncology Patients during Routine Practice.Transfusion 2008;48 (S1);36A
   
   
4. R Al-Radwan, L Lin, M Slaedts et al. Bacterial Contamination Residual Risks and Mitigations at the Kuwait Central Blood Bank.Transfusion 2008;48 (S1);108A-109A
   [Poster PDF]
   
   
5. K Dupuis, A Sampson-Johannes, J Kinsey et al. Inactivation of Influenza A H5N1 and Lymphocytic Choriomeningitis Virus (LCMV) by the INTERCEPT Blood System (IBS).Transfusion 2008;48 (S1);88A
   
   
6. D Hanson, R Mababangloob, N Patel et al. Robustness of Bacteria and Virus Inactivation with S-303 Treatment in RBC Concentrates at Variable Hematocrit (Hct). Transfusion 2008;48 (S1);89A-90A
   [Poster PDF]
   
   
7. AC Erickson, MA Schott, G Castro et al. Evaluation of In Vitro Quality of Stored RBC After Treatment with S-303 Pathogen Inactivation at Varying Hematocrit.Transfusion 2008;48 (S1);160A
   [Poster PDF]
   
   
8. AC Erickson, J Bayat, Y Gao et al. Evaluation of RBC Hydration After Treatment with S-303 Pathogen Inactivation at Varying Hematocrits (Hct).Transfusion 2008;48 (S1);229A
   [Poster PDF]
   
   

Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)
September 16 - 19, 2008 | Düsseldorf, Germany
[back to top]

1. V Witt, G Stiegler, P Höcker, H Gadner. Pathogen Inactivated Platelet Concentrates in Children. Transfus Med Hemother 2008;35(S1):4-5
   
   
2. R Henschler, HU Pfeiffer, M Wiesneth, M Müller, et al. Development of a Double-Dose Platelet Concentrate from 7 Buffy Coats Using the INTERCEPT Procedure for Pathogen Inactivation. Transfus Med Hemother 2008;35(suppl 1):58
   
   
3. L Sawyer, L Pinkoski, M Deane, T Peterson and P Carmichael. Pathogen Inactivation of Double Dose Platelets with the INTERCEPT Dual Storage Container Set. Transfus Med Hemother 2008;35(suppl 1):60-61
   [Poster PDF]

XXXth International Congress of the International Society of Blood Transfusion (ISBT)
June 7–12, 2008 | Macao, China
[back to top]

1. P Rasongles, F Knutson, O Garraud, R Tardivel, P Schlenke, M Lozano, L Barbolla, M Jacquet, L Lin, L Corash, D Sundin. Results from an Ongoing Hemovigilance Program Utilizing an Electronic Data Capture System to Characterize the Safety Profile of Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).Vox Sang 2008;95(Suppl 1):15
2. F Cognasse, JM Payrat, L Corash, JC Osselaer, O Garraud. Platelet Components Associated with Acute Transfusion Reactions: The Role of Platelet-Derived Soluble CD40-Ligand.
   Vox Sang 2008;95(Suppl 1):51
3. F Cognasse, JM Payrat, L Corash, JC Osselaer, O Garraud. Platelet Components Associated with Soluble CD40 Ligand-Associated Acute Transfusion Reactions: The Role of Pathogen Inactivation by Amotosalen.Vox Sang 2008;95(Suppl 1):160
4. R Garcia de Villaescusa, ML Ruiz Ayala, A Polo Escriche, MO Pinillos Garcia, F Antonanzas Villar. Pathogen Reduction of Platelets: Limitations of Economic Evaluations.
   Vox Sang 2008;95(Suppl 1):219
5. SJ Wagner, A Skripchenko, A Myrup, H Awatefe, D Thompson-Montgomery, G Moroff, P Carmichael and L Lin. The Effect of Amotosalen Photochemical Treatment (PCT) on the in Vitro Properties of Pooled, Individually-Leukoreduced, Whole Blood-Derived Platelets Stored in 100% Plasma.Vox Sang 2008;95(Suppl 1):263
6. JC Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Bosly, JS Lin, and L Corash. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use by Hematology Patients during Three Years of Routine Practice.Vox Sang 2008;95(Suppl 1):283
7. JC Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Bosly, JS Lin, and L Corash. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use in a Diverse Patient Population during Three Years of Routine Practice.Vox Sang 2008;95(Suppl 1):284
8. H Löf, F Knutson. INTERCEPT Technology Reduces the Number of Side Effects after Platelet Transfusions.Vox Sang 2008;95(Suppl 1):286
9. L Infanti, S Job, M Santoro, T Silzle, M Rüesch, C Stebler, J Halter, D Sundin, M Propst, L Lin, L Corash, A Gratwohl. Platelet Components Treated with Pathogen Inactivation using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Observational Trial in Switzerland. Vox Sang 2008;95(Suppl 1):289
10. JC Osselaer, C Doyen, L Defoin, S Vandenbossche, C Debry, M Goffaux, N Messe, M Van Hooydonk, L Corash, and L Lin. Impact of Amotosalen Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System) on the Response to Transfusion with 6- and 7-day Old Components.Vox Sang 2008;95(Suppl 1):291
11. MF Angelini-Tibert, P Simon, C Currie, L Corash, D Sundin, L Lin, P Rasonglès. Safety of Transfusing Split Platelet Components Prepared with Amotosalen Photochemical Treatment During a Chikungunya Virus Epidemic.Vox Sang 2008;95(Suppl 1):293
12. L Sawyer, L Pinkoski, M Deane, T Peterson and P Carmichael. Storage of INTERCEPT-Treated Double Dose Platelets in Two Containers.Vox Sang 2008;95(Suppl 1):299
13. L Sawyer, R Mababangloob, N Patel, J Kinsey and D Hanson. Pathogen Inactivation Achieved in Platelets Suspended in Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol.Vox Sang 2008;95(Suppl 1):299-300
14. J C Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, J Kerger, J S Lin, and L Corash. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use by Oncology Patients during Three Years of Routine Practice.Vox Sang 2008;95(Suppl 1):300
15. L Corash, J S Lin, J Eiden. Acute Lung Injury in Patients Receiving Repeated Platelet Transfusions. Vox Sang 2008;95(Suppl 1):300-301
16. A Brussel, A Vandercappellen, L Lin, M Steiert. Evaluation of Viral and Bacterial Inactivation in Platelet Concentrates Suspended In 100% Plasma Treated with the INTERCEPT Blood System.Vox Sang 2008;95(Suppl 1):301
17. D Kientz, H Isola, ML Wiesel, M Laforet, F Bigey, JP Cazenave. Validation of Apheresis Concentrated Platelet Collection in Additive Solution with the MCS+ Device, for Pathogenic Inactivation with the Amotosalen Photochemical Process and UVA Light.Vox Sang 2008;95(Suppl 1):307
18. JP Cazenave, C Waller, I Mendel, D Kientz, G Kandel, JP Raidot, ML Wiesel, M Laforet, H Isola. Clinical Experience with Conventional Versus INTERCEPT Platelet Concentrates Transfused to all Patients During Two One-Year Periods: Reduction of Adverse Events with Equivalent Use of Blood Products.Vox Sang 2008;95(Suppl 1):305-306
19. JP Cazenave, ML Wiesel, I Mendel, D Kientz, A Faradji, S Mangeant, B Perricard. Intensive and Successful Transfusion of Pathogen Inactivated INTERCEPT Platelet Concentrates for Major Gynecological and Obstetrical Surgery in Glanzmann Thrombasthenia Type 1 with the Gypsy Mutation.
    Vox Sang 2008;95(Suppl 1):306
20. R Henschler, M Wiesneth, HU Pfeiffer, M Mueller, L Lin, L Corash, E Seifried. Generation of Double Dose Platelet Concentrates from Pooled Buffy-Coats for Pathogen Inactivation with INTERCEPT.Vox Sang 2008;95(Suppl 1):315
21. M Steiert, E Castro, P Grellier, J Benach, WC Van Voorhis, RT Eastman, K Dupuis, L Sawyer, L Lin. Photochemical Inactivation with Amotosalen and UVA Light of Protozoan Parasites in Platelet and Plasma Components Using INTERCEPT Blood System.Vox Sang 2008;95(Suppl 1):291
22. K Dupuis and L Sawyer. Inactivation of Influenza Virus Type A H5N1 in Platelets and Plasma by Treatment with the INTERCEPT Blood System.Vox Sang 2008;95(Suppl 1):301

Congreso Nacional de la Sociedad Espanola de Transfusion Sanguinea (SETS)
May 29 - 31, 2008 | Cadiz, Spain
[back to top]

1. JC Osselaer, J Irsch, L Corash. Treatment of Platelet Components for Pathogen Inactivation with the INTERCEPT Blood System Allows for 7-Day Storage: Impact on Organization and Economics in Blood Centers.
   
   
2. L Barbolla, M Algora, M Jurado, M Lozano, T Cedena, F Gilsanz, P Rasongles, F Knutson, O Garraud, R Tardivel, P Schlenke, M Jacquet, L Lin, L Corash, D Sundin. Results from an Ongoing Hemovigilance Program Characterizing the Safety Profile of Platelet Transfusions Treated with Photochemical Treatment (INTERCEPT Blood System).

2007 ABSTRACTS

Jump to conference:
November - ASH
November - TRIP
October - AABB, JSBT
September - DGTI, SIMTI
June - ISBT
March - PI Consensus Conference

The American Society of Hematology 49th Annual Meeting and Exposition (ASH)
December 8 –11, 2007 | Atlanta, Georgia     
[back to top]

1. JC Osselaer, C Doyen, C Graux, C Chatelain, A Sonnet, M Jacquet, JS Lin, L Corash, A Bosly. Prevention of Transfusion-Associated Graft Versus Host Disease (TA-GVHD) by Photochemical Treatment of Platelet Components: Clinical Experience in Routine Use.
   Blood 2007;110(11):849A
2. JC Osselaer, JP Cazenave, C Waller, M Lambermont, O Garraud, P Fabrigli, M Hidajat, D Dehenau, L Barbolla, JL Arroyo, R Tardivel, M Jacquet, D Sundin, L Lin, L Corash. An Active Hemovigilance Program Characterizing the Safety Profile of 7,437 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).
   Blood 2007;110(11):852A
3. JD Roback, H Isola, L Lin, JP Cazenave. Inactivation of Infectious CMV in Platelet Products: Comparison of INTERCEPT Blood System and Leukofiltration.
   Blood 2007;110(11):849A
4. JP Cazenave, P Netzer, S Schuhler, C Ravanat, H Isola, D Kientz, C Gachet, ML Wiesel. Retention of Thrombin Generation Capacity of Therapeutic Apheresis Plasma Prepared with Amotosalen and UVA Light (INTERCEPT) Pathogen Inactivation.
   Blood 2007;110(11):75B

Transfusion Reaction in Patients Foundation (TRIP) Symposium Hemo-en Weefselvigilantie November 29, 2007 | Utrecht, The Netherlands
[back to top]

1. MF Angelini-Tibert, M Slaedts, J Irsch, LM Corash, P Rasonglès. Reduction in Acute Transfusion Reactions in Pediatric Hematology-Oncology Patients Transfused with INTERCEPT Platelets.
   
2. MF Angelini-Tibert, P Simon, M Slaedts, J Irsch, L Corash, P Rasonglès. INTERCEPT Platelets Demonstrate Safety During a Chikungunya Virus Epidemic.
   
3. JC Osselaer, C Doyen, C Chatelain, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Sonnet, A Bosly, JS Lin, L Corash. Three Years of Experience with the INTERCEPT Blood System (IBS) for Pathogen Inactivation: Impact on Platelet Utilization in a Routine Use Environment.

American Association of Blood Banks Annual Meeting & TXPO (AABB)
October 20 –23, 2007 | Anaheim, California, USA
[back to top]

1. RE Agliastro, G De Francisci, R Bonaccorso, D Spicola, G D’Alia, D Bellavia, D Ferrara, A Ferrante Bannera, A Giancana, B Giancana, A Mazzola, G Nuara. Report of Four Years of Experience in Production and Clinical Efficacy of Pathogen-Inactivated Platelets.
   Transfusion 2007;47 (S3):128A-129A
2. MF Angelini-Tibert, P Simon, C Currie, M Slaedts, L Corash, P Rasonglès. Safety of Platelet Components Prepared with Photochemical Treatment Transfused During a Chikungunya Virus Epidemic.
   Transfusion 2007;47 (S3):19A-20A
3. MF Angelini-Tibert, C Currie, M Slaedts, LM Corash, P Rasonglès. Safety of Platelet Components Prepared with Photochemical Treatment (INTERCEPT) Transfused to Pediatric Oncology-Hematology Patients.
   Transfusion 2007;47 (S3):22A
4. ME Brecher, SN Hay, LM Corash, J Hsu, L Lin. Evaluation of Bacterial Inactivation in Pre-storage Pooled, Leukoreduced, WB-Derived Platelet Concentrates Suspended in Plasma Prepared with Photochemical Treatment.
   Transfusion 2007;47 (S3):130A-131A
5. S Lam, HC Tan, LK Tan, L C Ng, D Teo, M Koh. Efficacy of INTERCEPT Treatment for the Inactivation of Dengue Virus in Single-Donor Platelet Concentrate.
   Transfusion 2007;47 (S3):131A-132A
6. JC Osselaer, C Doyen, C Chatelain, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Sonnet, A Bosly, JS Lin, L Corash. Impact of Pathogen Inactivation (INTERCEPT Blood System)
   on Platelet Utilization During Three Years of Routine Use.
   Transfusion 2007;47 (S3):18A-19A
7. D Rigal, Y Merieux, O Garraud, C Courvoisier, LM Corash, M Debos. Conservation of Human Platelet Antigen (HPA) Immunologic Identity After Photochemical Treatment of Platelet Concentrates with Amotosalen (S-59) and UVA Light.
   Transfusion 2007;47 (S3):136A
8. JD Roback, H Isola, N Saakadze, L Lin, JP Cazenave. CMV Safety of Platelet Products: Comparison of Inactivation by INTERCEPT Blood System and Removal by Leukofiltration.
   Transfusion 2007;47 (S3):23A
9. SJ Wagner, A Skripchenko, A Myrup, H Awatefe, D Thompson-Montgomery, G Moroff, P Carmichael, L Lin. The Effect of Photochemical Treatment (PCT) on the in vitro Properties of
   Pooled Whole-Blood-Derived Leukoreduced Platelets Stored in 100% Plasma.
   Transfusion 2007;47 (S3):129A

Japanese Society for Blood Transfusion (JSBT)
October 5–6, 2007 | Takamatsu City, Japan
[back to top]

1. RJ Benjamin. The American Red Cross Experience with Bacterial Culture of Platelets: Test Failures Highlight the Need for Robust Pathogen Inactivation Systems.
   

Società Italiana di Medicina Trasfusionale e Immunoematologia (SIMTI)
September 24 –26, 2007 | Stresa, Italy
[back to top]

1. R E Agliastro, G De Francisci, R Bonaccorso, D Spicola, G D’Alia, D Bellavia, D Ferrara, A Ferrante Bannera, A Giancana, B Giancana, A Mazzola, G Nuara. Report of Four Years of Experience in Production and Clinical Efficacy of Pathogen-Inactivated Platelets.

German Society for Transfusion Medicine and Immunohematology (DGTI)
September 18 –21, 2007 | Friedrichshafen, Germany
[back to top]

1. P Schlenke, W Hagenah, S Andresen, M Bauhaus, D Sundin, L Lin, L Corash, T Wagner, H Kirchner. Pathogen Inactivated Platelets Using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Trial in Germany.
   Transfus Med Hemother 2007;34(S1):1-74

International Society for Blood Transfusion (ISBT)
June 24-27, 2007 | Madrid, Spain      
[back to top]

1. O Garraud, P Fabrigli, R Tardivel, H Gouezec, C Waller, I Mendel, J. P. Raidot, G. Kandel, H. Isola and JP Cazenave. Hemovigilance for Transfusion of INTERCEPT™ Platelets in Routine Therapeutic Use: Experience in Établissement Français du Sang (EFS) Blood Centers
   
2. JP Cazenave, I Metzger, J Dréno, H Isola, N Léon, and A Chicoye. Net Cost Impact of Implementation of Photochemical Pathogen Inactivation (INTERCEPT Blood System™ for platelets) for Preparation of Platelet Components.
3. H Isola, D Kientz, ML Wiesel, M Laforêt, P Ohlmann, C Waller, I Mendel, JP Raidot, G Kandel, and JP Cazenave. Implementation of Photochemical Pathogen Inactivation (INTERCEPT Blood System™ for Platelets) in a Regional Blood Center.
   [Poster PDF]
   
4. L Defoin, C Doyen, C Debry, M Goffaux, N Messe, M Van Hooydonk, L Corash, and JC Osselaer. Impact of Photochemical Pathogen inactivation Treatment (INTERCEPT Blood System™ for Platelets, IBSP) on the Response to Transfusion with 6 and 7-Day Old Components.
   [Poster PDF]
5. E Castro, JL Bueno, P Rodríguez, L Barea and R Gonzalez. Three Years of Experience with the INTERCEPT™ Blood System for Apheresis Platelets in Routine Use
   [Poster PDF]
6. P Schlenke, W Hagenah, S Andresen, M Bauhaus, D Sundin, L Lin, L Corash, T Wagner, H Kirchner. Platelet Components Treated with Pathogen Inactivation Using the INTERCEPT™ Blood System: Clinical Outcomes of the First Single-Centre Clinical Trial in Germany.
   [Poster PDF]
7. P Schlenke, W Hagenah, S Andresen, M Bauhaus, L Lin, T Wagner, H Kirchner. Platelet Concentrates Treated for Pathogen Inactivation Using the INTERCEPT™ Blood System: Manufacturing and Quality Control of INTERCEPT Platelets in Routine.
   [Poster PDF]
8. C Stebler, L Infanti, M Rüesch, H Lüscher, S Job, J Pfenninger, A Gratwohl, J Tobler. A Comparison of Transfusion of Standard and Pathogen Inactivated (INTERCEPT™) Platelets with Regards to CCI and Acute Transfusion Reactions in Hematological Patients.
   [Poster PDF]
9. C Stebler, M Rüesch, M Santoro, H Lüscher, S Job, J Pfenninger, L Infanti. Pathogen Inactivation of Double Dose Apheresis Platelets Using the INTERCEPT™ Blood System: Logistical and Financial Cost Benefits and Clinical Efficacy.
   [Poster PDF]
10. G Lambermont, N Cellier, R De Meuter. One Year of Routine Use of the INTERCEPT Blood System for Platelet Pathogen Inactivation: Product Preparation and Clinical Evaluation.
11. Z Cermakova, J Marcalikova, M Stachelova. Storage of Apheresis Platelet Concentrates Treated with INTERCEPT System.
    
12. L Sawyer, A Sampson-Johannes, T Dubensky, J Kinsey, DL Vanlandingham, K Tsetsarkin and S Higgs. Inactivation of Chikungunya Virus in Plasma and Platelets Using the INTERCEPT Blood System™.
    [Poster PDF]
13. L Sawyer, L Corten, D Hanson and L Lin. Robustness Of Viral Inactivation In High-Dose INTERCEPT Platelets.
    [Poster PDF]

CBS & Héma-Québec Pathogen Inactivation Consensus Conference
March 29-30, 2007 | Toronto, Canada
[back to top]

1. JC Osselaer, C Doyen, C Chatelain, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Sonnet, A Bosly, JS Lin, and L Corash. Impact of Photochemical Treatment (INTERCEPT Blood System for Platelets, IBSP) on Platelet Use in Routine Practice: A Three Year Experience.
   [Poster PDF]
2. L Defoin, C Doyen, C Debry, M Goffaux, N Messe, M Van Hooydonk, L Corash, and JC Osselaer. Impact of Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System for Platelets, IBSP) on the Response to Transfusion with 6 and 7- Day Old Components.
   [Poster PDF]
3. E Castro, N Gironés, JL Bueno, J Carrión, M Fresno. The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for Inactivation of T. cruzi in Buffy Coat Platelet Components.
   [Poster PDF]
4. E Castro and JL Bueno. Three Years of Routine Use Experience with the INTERCEPT Blood System for Platelets.
   [Poster PDF]
5. P Schlenke, W Hagenah, S Andresen, M Bauhaus, D Sundin, L Lin, L Corash, T Wagner, H Kirchner. Platelet Components Treated with Pathogen Inactivation Using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Clinical Trial in Germany.
   [Poster PDF]

2006 ABSTRACTS

Jump to conference:
December - ASH
October - AABB
September - DGTI
September - ISBT
June - SETS
April - NATA
March - EBMT
March - ICEID
February - EBMT

American Society of Hematology (ASH)
December 9-12, 2006 | Orlando, Florida, USA      
[back to top]

1. L Corash, F Cognasse, JC Osselaer, N Messe, M Van Hooydonk and O Garraud. Cytokines In Platelet Components Associated With Acute Transfusion Reactions: The Role of sCD40L.
   [Poster PDF]
2. L Corash, F Cognasse, JC Osselaer, N Messe and O Garraud. Release of Immune Modulation Factors From Platelet Concentrates During Storage After Photochemical Pathogen Inactivation.
   [Poster PDF]

American Association of Blood Banks (AABB)
October 21-24, 2006 | Miami Beach, Florida, USA      
[back to top]

1. L Corash,P Rasonglès, H Isola, D Kientz, L S Sawyer, J Cazenave. Photochemical Pathogen Inactivation for Preparation of Platelet Components During an Epidemic of Chikungunya Virus.
   [Poster PDF]
2. Sawyer L, Hsu J, Bernard K, Sampson-Johannes A, Dupuis K, Pinna D, Lane R, Grellier P, Van Voorhis W, Benach J, Lin L. Inactivation of Emergent Blood-borne Pathogens in Plasma and Platelets.
   [Poster PDF]

Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)
September 19-22, 2006 | Frankfurt, Germany
[back to top]

1. K. Janetzko, P. Bugert, L. Lin, and H. Klüter. Monitoring of the Photochemical Pathogen Inactivation Procedure for Platelet Concentrates by PCR and Bioanalyzer.
   
2. Peter Schlenke, Valentine Franck, Lily Lin, Wiebke Hagenah, Silke Wehmeier. In VITRO and in VIVO Evaluation of Platelet Concentrates Treated with Pathogen Inactivation Using the INTERCEPT Blood System.
   

International Society for Blood Transfusion (ISBT)
September 2-7, 2006 | Cape Town, South Africa
[back to top]

1. P Rasonglès, H Isola, D Kientz, J-P Cazenave, L Sawyer, L Corash. Rapid Implementation of Photochemical Pathogen Inactivation (INTERCEPT) for Preparation of Platelet Components During an Epidemic of Chikungunya Virus.
2. A Ontanon, I Romon, C Hurtado, J Hsu, L Lin, V Hermosa.  Inactivation of High Levels of Bacteria Using the INTERCEPT Blood System Under Routine Blood Bank Procedures.
   [poster PDF]
3. JC Osselaer, N Messe, T Hervig, JL Bueno, E Castro, A Espinosa, A Iacone, K Junge, M Jacquet, J Flament, L Corash.  A Prospective Observational Cohort Safety Study of 5,106 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).
   [poster PDF]
4. JC Osselaer, C Doyen, C Chatelain, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Sonnet, A Bosly, J-S Lin, L Corash. Impact of Photochemical Treatment (INTERCEPT) on Platelet Use In Routine Practice.
   [poster PDF]
5. JC Osselaer, C Debry, M Goffaux, M Van Hooydonk, V Mayaudon, L Lin, L Corash. Photochemical Pathogen Inactivation of High-dose Apheresis Platelet Concentrates Using the INTERCEPT Blood System.
   [poster PDF]
6. P Schlenke, V Franck, L Lin, H Kirchner. Storage of Apheresis and Pooled Buffy-coat Platelet Concentrates Treated with Pathogen Inactivation Using the INTERCEPT Blood System.
   [poster PDF]
7. I Van Haute, S Van Lancker, V Bordon, Y Benoit. Therapeutic Effi cacy and Safety of Transfusion of Pathogen-Inactivated Platelets to Pediatric Patients.
   [poster PDF]
8. V Witt, G Fischmeister, G Stiegler, P Höcker, H Gadner. Transfusion of Pathogen Inactivated Platelet Concentrates in Children.
9. C Vignoli, AM Dombey, JF Cantaloube, V Mayaudon, L Lin, P De Micco, P Gallian. Photochemical Treatment with Amotosalen and UVA Light Inactivated High Titers of an Emerging South France Viral Strain of West Nile Virus.
   [poster PDF]
10. G Stiegler, V Witt, P Mörtl, G Leitner, P Höcker. Routine Production of INTERCEPT-Treated Apheresis Platelet Concentrates for Pediatric Patients.
11. E Castro, N Gironés, JL Bueno, J Carrión, M Fresno. The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for the Inactivation of Trypanosoma cruzi (T.cruzi) in Buffy Coat Derived Platelet Components.
    [poster PDF]
12. R De Meuter, G Bastin, M Lambermont. Evaluation of the INTERCEPT Blood System for Amicus Apheresis Platelet Concentrates: Meeting Target Product Characteristics.
13. L Sawyer, K. Dupuis, A. Sampson-Johannes, T. Dubensky, D.L. Vanlandingham, K. Tsetsarkin S. Higgs. Inactivation of Chikungunya Virus in Plasma and Platelets Using Helinx Technology, as Utilized in the INTERCEPT Blood System.
    [poster PDF]
    

Sociedad Espanola de Transfusion Sanguinea  (SETS)
June 8-10, 2006 | Palma de Mallorca, Spain     
[back to top]

1. A Ontañón, I Romón, C Amunarriz, V Hermosa, J Hsu, C Hurtado, M Ostalaza, A Marina, M Ojea, A Rico, M López, C González, M Diez-Velasco, S Fernández.  Evaluation Of INTERCEPT Blood System® (Baxter-Cerus) For Pathogen Inactivation: The Effect Of Implementation On The Quality Of The Platelets And On The Logisitcs Of The Centre.
   [poster PDF]

Network for Advancement of Transfusion Alternatives (NATA)
April 6-7, 2006 | Malaga, Spain
[back to top]

1. M Lozano, A Galan, R Mazzara, L Corash, G Escolar. Hemostatic function of Leucocyte-Reduced Buffy Coat Derived Platelet Concentrates (BCPC) Treated With INTERCEPT® Are Well Conserved After 7 Days of Storage: Studies In A Whole Blood Flow System.

European Group for Blood and Marrow Transplantation (EBMT)
March 23-24, 2006 | Hamburg, Germany     
[back to top]

1. P Schlenke, L Lin, L Corash and M Conlan. Protection Against TA-GvHD in Blood Transfusion: Is Gamma-irradiation the Only Answer?
   [poster PDF]

International Conference on Emerging Infectious Diseases (ICEID)
March 19-22, 2006 | Atlanta, Georgia     
[back to top]

1. L Sawyer, J Benach, K Bernard, K Dupuis, P Grellier, JC Hsu, R Lane, L Lin, A Sampson-Johannes, W van Voorhis, E Vicenzi.   Inactivation of Emergent Blood-borne Pathogens in Plasma and Platelets Using the INTERCEPT Blood System.
   [poster PDF]
   

American Society for Blood and Marrow Transfusion (ASBMT)
February 16-20, 2006 | Honolulu, HI, USA     
[back to top]

1. C Grabmer, C Lass-Floerl, D Allersdorfer, M Rheinschmidt, L Lin, D Schoenitzer and W Nussbaumer. Bacterial Contamination of Platelet Concentrates: Inactivate or screen?
   [poster PDF]

2005 ABSTRACTS

Jump to conference:
December - ASH
November - ISBT (Bangkok)
October - AABB
September - GSTMI
July - ISBT (Athens)
June - SFTS, EHA
March - EBMT

American Society of Hematology (ASH)
December 2005, Atlanta | Georgia, USA      
[back to top]

1. E Castro, N Gironés, JL Bueno, J Carrión, M Fresno. The efficacy of photochemical treatment with amotosalen and UVA (INTERCEPT) inactivation of T. cruzi in buffy coat platelet components.
2. M Lozano, A Galan, R Mazzara, L Corash, G Escolar. Leucocyte-reduced buffy coat platelet concentrates (BCPC) treated with INTERCEPT stored up to 7 days: hemostatic function in a whole blood flow system.
3. JC Osselaer, C Doyen, N Messe, M Van Hooydonk, M Jacquet, A Sonnet, A Bosly, J Flament, LCorash. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and resources.

International Society of Blood Transfusion (ISBT)
November 2005, Bangkok | Thailand      
[back to top]

1. L Sawyer, R Mababangloob, M Propst, A Sampson-Johannes, K Bernard, B Guillmand, K Murthy, K Dupuis. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT blood system.
2. M Conlan, D Vesole, E Stadtmauer, L Goodnough, S Coutre, F Howard, J-S Lin. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation: results of the phase III Sprint trial of INTERCEPT platelets.

American Association of Blood Banking (AABB)
October 2005, Seattle | Washington, USA      
[back to top]

1. D Pinna, L Lin, E Vicenzi. Photochemical inactivation of SARS-CoV in platelet concentrates: comparison of a PCR inhibition assay to an infectivity assay.
2. I Van haute, Y Benoit, E Vandecruys, B De Moerloose, S Van Lancker, K Mattheeuws, B Vandekerckhove. Therapeutic effi cacy and safety of transfusion of pathogen-inactivated platelets to pediatric patients.
3. C Lass-Flörl, D Allersdorfer, M Rheinschmidt, L Corash, L Lin, D Schönitzer, W Nussbaumer. Comparison of BactAlert® and INTERCEPT™ in preventing the release of platelet units containing low numbers of viable bacteria.
4. M Lozano, L Arenillas, D Perea, M Jané, MJ Lachén, R Mazzara . Pilot study of routine use of INTERCEPT treated buffy coat derived platelet concentrates.
5. B Curtis, S Graminske, A Lochowicz, E Castro, L Lin, J Flament, P Metzel, L Corash. Conservation of human platelet antigen (HPA) immunologic identity after photochemical treatment of platelet components with amotosalen (S-59) and UVA light.

German Society of Transfusion Medicine and Immunohaematology
September 2005, Erfurt | Germany
[back to top]

1. C Lass-Flörl, D Allersdorfer, M Rheinschmidt, L Corash, L Lin, D Schönitzer, W Nussbaumer. Bacterial contamination of platelets - screen or inactivate?

International Society of Blood Transfusion (ISBT)
July 2005 | Athens, Greece      
[back to top]

1. AC Simonsen, PI Johansson, J Flament, M Jacquet, J-S Lin, K Junge, H Sørensen, N Borregaard, M Conlane. Transfusion of thrombocytopenic patients using INTERCEPT platelets prepared with photochemical treatment with amotosalen and UVA light and stored for 7 days: results of a pilot study.
2. C Lass-Flörl, D Allersdorfer, M Rheinschmidt, L Lin, D Schönitzer, W Nussbaumer. Comparative efficacy of bacterial culture versus pathogen inactivation to reduce the risk of transfusion-associated sepsis.
3. JC Osselaer, JL Bueno, N Messe, M Jacquet, E Castro, J Flament . Prospective active hemovigilance plan for INTERCEPT platelets in Europe: a status report.
4. G Santos, C Silva, F Pereira, G Sousa. Validation of INTERCEPT treatment of pooled platelets.

Society of French Transfusion Sanguine (SFTS)
June 2005 | St. Malo, France      
[back to top]

1. C Lass-Flörl, D Allersdorfer, M Rheinschmidt, L Lin, D Schönitzer and W Nussbaumer. Comparative efficacy of bacterial culture versus pathogen inactivation to reduce the risk of transfusion-associated sepsis.
2. J Osselaer, N Messe, M Goffaux, M Van Hooydonck, C Doyen, A Bosly. Une expérience de 15 mois d’utilisation d’INTERCEPT pour l’inactivation des agents pathogènes dans les concentrés plaquettaires.
3. L Corash, L Sawyer, R Mababangloob, M Propst, A Sampson-Johannes, K Bernard, P Grellier, B Guillmand, Murthy, W Van Voorhis and K Dupuis. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT Blood System.
4. Jauneau, S Le Quere, AG Leaute, C Chuteau, C Adjou, G Laurent, G Follea. Evaluation in vitro de concentres de plaquettes d’apherese (cpa) preleves sur separateur spectra et inactives par intercept blood system apres reduction du volume de plasma.
5. Van haute,Y Benoit, E Vandecruys, B de Moerloose , S Van Lancker, K Mattheeuws and B Vandekerckhove. Safety and effi cacy of pathogen-inactivated platelets transfused in routine use to pediatric patients: an interim report.

European Hematology Association (EHA)
June 2005 | Stockholm, Sweden
[back to top]

1. L Sawyer, R Mababangloob, M Propst, A Sampson-Johannes, K Bernard, P Grellier, B Guillmand, K Murthy, W Van Voorhis and K Dupuis. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT Blood System.

European Group for Blood and Marrow Transplantation (EBMT)
March 2005, Prague | Czech Republic
[back to top]

1. J Roback, L Lin, L Corash. Prevention of transfusion-transmitted CMV infection: a murine model.

2004 ABSTRACTS

Jump to conference:
December - ASH
October - AABB
September - DGTI
July - ISBT
June - ISHEID
February - ASBMT

American Society of Hematology (ASH)
December 2004 | San Diego, California, USA      
[back to top]

1. Y Benoit, I VanHaute, E Vandecruys, B DeMoerloose, S VanLancker, K Mattheeus and B Vandekerckhove. Safety and efficacy of pathogen-inactivated platelets transfused in routine use to pediatric patients: an interim report.
2. JC Osselaer, C Doyen, A Sonet, M VanHooydonk, E Goosenhaerts, C Chatelain, A Bosly and L Corash. Routine use of platelet components prepared with photochemical treatment (INTERCEPT Platelets): impact on clinical outcomes and costs.
3. K Moeremans, H Warie, L Annemans, T Digneffe, J Toté and L Corash. Assessment of the economic value of the INTERCEPT Blood System for platelets in Belgium.

American Association of Blood Banks (AABB)
October 2004 | Baltimore, Maryland, USA      
[back to top]

1. D Hanson, K Dupuis and L Sawyer. Inactivation of Parvovirus B19 in platelets by Helinx® technology.

Deutschen Gessellschaft für Transfusionsmedizin und Immunhämatologie e.V. (DGTI) September 2004 | Mannheim, Germany      
[back to top]

1. D Chen, B Donnelly, T Taga, R Murphey, R Mababangloob, L Sawyer and L Lin. INTERCEPT Platelets from Trima collection system retain function, demonstrate inactivation of key pathogens, and meet Council of Europe standards.
2. D Chen, B Donnelly, A Blair, L Rose, T Taga, R Murphey, L Sawyer, L Lin. INTERCEPT Platelets from Haemonetics MCS+ ® and Cobe Spectra demonstrate pathogen inactivation, retain function, and meet Council of Europe standards.
3. K Dupuis, A Sampson-Johannes, K Bernard and L Sawyer. Helinx® technology inactivates high titers of SARS-CoV, WNV and Vaccinia in platelet concentrates.

International Society of Blood Transfusion (ISBT)
July 2004 | Edinburgh, Scotland      
[back to top]

1. T Sullivan andT McCullough. Assessment of safety for the INTERCEPT® Blood System for platelets in neonatal preclinical model.
2. B Donnelly, L Sawyer and L Lin. Similar in vitro function and bacterial inactivation, leukoreduced (Lr) vs non-Lr INTERCEPT Platelets.
3. K Dupuis, A Sampson-Johannes, K Bernard. Helinx® technology inactivates high titers of SARS-CoV, WNV and Vaccinia in INTERCEPT Platelets.
4. MG Conlan, L Corash, J Flament, DH Buchholz, S Van Doren, S Porter for the euroSPRITE, SPRINT and STEP Study Groups. INTERCEPT Platelets & Plasma do not result in neoantigenicity: results of 7 phase 3 clinical trials.

International Symposium on HIV & Emerging Infectious Diseases (ISHEID)
June 2004, Toulon | France
[back to top]

1. L Sawyer, K Dupuis, A Sampson-Johannes and K Bernard. Helinx technology inactivates high titers of SARS-CoV, WNV and Vaccinia in platelet concentrates.

American Society for Blood and Marrow Transplantation (ASBMT)
February 2004 | Orlando, Florida, USA
[back to top]

1. D Vesole, E Stadtmauer, LT Goodnough, S Coutre, F Howard, J-S Lin, and MG Conlan for the SPRINT Study Group. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III SPRINT trial of INTERCEPT pathogen-inactivated platelets.

2003 ABSTRACTS

Jump to conference:
December - ASH
November - NHF, AABB
October: ISFA, IDSA
September: DGTI, ICAAC, ESFH, ESP
July: EBMT, ISTH, ISBT
June: ISATS, NATA, EHA
May: ISPOR, PAS
January: ASBMT

The American Society of Hematology 45th Annual Meeting and Exposition (ASH)
December 2003 | San Diego, California, USA      
[back to top]

1. Murphy S, Snyder E, Cable R, et al. Transfusion of INTERCEPT platelets vs. reference platelets at doses ≥3.0x10¹¹ results in comparable hemostasis and platelet and RBC transfusion requirements: Results of the SPRINT trial.
2. Dupuis K, Sampson-Johannes A. The causative agent of SARS in platelet and red cell concentrates is inactivated by Helinx technology.
3. Bruchmüller I, Janetzko K, Bugert P, et al. Use of a PCR inhibition assay to monitor the photochemical pathogen inactivation process by Helinx technology is feasible.

The National Hemophilia Foundation's 55th Annual Meeting (NHF)
November 2003 | Salt Lake City, Utah, USA      
[back to top]

1. Sawyer L, Dupuis K, Sampson-Johannes A, et al. Helinx technology inactivates hight titers of traditional and emerging viruses in platelet concentrates and plasma.

The 56th Annual Meeting of the American Association of Blood Banks (AABB)
November 2003 | San Diego, California, USA      
[back to top]

1. Lopez-Plaza I, Snyder E, Goodnough L, et al. INTERCEPT platelet transfusions are associated with fewer transfusion reactions than conventional platelet transfusions prepared by apheresis with process leukoreduction.
2. Lin L, Porter S, Lin J-S, and Conlan M. Multiple transfusions of platelet concentrates treated with amotosalen and UVA for pathogen inactivation did not result in amotosalen accumulation in patient plasma.
3. Benjamin R, Goodnough L, Lopez-Plaza I, et al. Fresh (1-2 day-old) vs. aged (4-5 day-old) INTERCEPT platelets and conventional platelets provide comparable count increments, however, fresh platelets result in superior hemostasis: results of the SPRINT trial.
4. Bernard K, Jones S, Dupuis K. West Nile Virus is inactivated by Helinx technology in human platelet concentrates.
5. Rentas F, Lippert L, Harman R, et al. Inactivation of Orienta tsutsugamuchi in an animal model using the INTERCEPT Blood System for platelets.
6. Sampson-Johannes A, Sawyer L. Helinx technology inactivates vaccinia virus in human platelet concentrates.
7. Donnelly B, Chen A, Blair A, et al. INTERCEPT Platelets from Haemonetics MCS+ and Cobe Spectra Systems demonstrate inactivation of key pathogens, retain function, and meet AABB standards.
8. Donnelly B, Taga T, Murphey R, et al. INTERCEPT Platelets from Trima Collection System retain function, demonstrate inactivation of key pathogens, and meet AABB standards.
9. Ciaravino V, Sullivan T, McCullough T. The absence of reproductive toxicity demonstrated by the INTERCEPT Blood System for platelets.

The 4th World Congress of the International Society for Apheresis (ISFA)
November 2003 | Nashville, Tennessee, USA      
[back to top]

1. Donnelly B, Bartram M, Chen D, et al. INTERCEPT Platelets treated for pathogen inactivation from Haemonetics MCS+ and Cobe Spectra Systems are similar to Amicus Separator and meet AABB standards.
2. Donnelly B, Bartram M, Murphey R, et al. INTERCEPT Platelets treated for pathogen inactivation from Trima Collection System are similar to Amicus Separator and meet AABB standards.

The 41st Annual Meeting of the Infectious Diseases Society of America (IDSA)
October 2003 | San Diego, California, USA      
[back to top]

1. Van Voohis W, Barrett L, Eastman R, Dupuis K. Inactivation of Trypanosoma cruzi and Leishmania mexicana in human platelet concentrates and plasma by amotosalen HCl and UVA illumination.

The 36th Congress of the Deutsche Gesellschaft für Transfusionsmedizin und Immunhümatologie (DGTI)
September 2003 | Innsbruck, Austria     
[back to top]

1. Dupuis K, Sampson-Johannes A, Corash L. The INTERCEPT Blood System for platelets inactivates the causative agent of SARS.

The 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 2003 | Chicago, Illinois, USA      
[back to top]

1. Sawyer L, Dupuis K, Bernard K, et al. Helinx technology inactivates high titers of a variety of blood-borne pathogens in platelets.

The 14th Congress of the European Society for Haemapheresis and Haemotherapy (ESFH) September 2003 | Prague, Czech Republic     
[back to top]

1. Conlan M. The INTERCEPT Blood System for platelets provides pathogen inactivation while maintaining platelet therapeutic efficacy.

The 10th Annual Congress of the European Society for Photobiology (ESP)
September 2003 | Vienna, Austria     
[back to top]

1. Hearst JE. Psoralen from lab bench, through clinical trials, to the market.

The 29th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT)
July 2003 | Istanbul, Turkey     
[back to top]

1. Sullivan T, Ciaravino V, McCullough T. No clinically relevant toxicity shown in the preclinical safety assessment of the INTERCEPT Blood System for platelets.
2. Conlan M, Lin J-S, Flament J, et al. INTERCEPT Platelets treated with Helinx technology to inactivate T-cells prevented Transfusion-Associated Graft vs. Host Disease (TA-GVHD): Results of 3 clinical trials.

The 19th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
July 2003 | Birmingham, UK     
[back to top]

1. Ciaravino V, Cimino G, McCullough T. Preclinical safety assessment of photochemically-treated platelets: No toxicologically relevant effects with large multiples of the clinical exposure.

The 8th Regional European Congress of the International Society of Blood Transfusion (ISBT)
July 2003 | Istanbul, Turkey     
[back to top]

1. Snyder E, Slichter S, McCullough J, et al. INTERCEPT Platelets provided acceptable therapeutic responses during multiple transfusion cycles: The SPRINT Trial.
2. Ciaravino V, McCullough T, Sullivan T, Corash L. No toxicity observed in a 3-month study in beagle dogs administered autologous platelets treated with the INTERCEPT Blood System.
3. Conlan M, Lin J-S, Flament J, et al. INTERCEPT Platelets treated with Helinx technology to inactivate T-cells prevented Transfusion-Associated Graft vs. Host Disease (TA-GVHD): Results of 3 clinical trials.
4. Dupuis K, Alfonso R, Savoor A, et al. Helinx technology, used in the INTERCEPT Blood System, inactivates high titers of emerging insect-borne pathogens in platelets and red cells.

The XXI Congres de la Societe Francaise de Transfusion Sanguine (SFTS)
June 2003 | Saint-Etienne, France     
[back to top]

1. Dupuis K, Alfonso R, Grellier P, Labaied M. The INTERCEPT Blood System for platelet concentrates inactivates Plasmodium falciparum.
2. Dupuis K, Alfonso R, Hanson D, et al. Helinx technology inactivates high titers of transfusion-transmitted pathogens in platelets.
3. Dupuis K, Alfonso R, Guilleman B, Jauvin V. The INTERCEPT Blood System for platelet concentrates inactivates Human T-cell Lymphotropic Virus Types I and II (HTLV-I & -II).
4. Ciaravino V, Payrat JM. Pharmacokinetic and toxicology assessment of INTERCEPT Platelets: No toxicologically relevant effects.

The International Symposium on Advances in Transfusion Safety (ISATS)
June 2003 | Bethesda, Maryland, USA      
[back to top]

1. Conlan M, Flament J. Helinx-treated platelets provide effective hemostasis and count increments: Comparison to conventional platelets in 2 Phase 3 clinical trials.
2. Conlan M, Lin J-S, Flament J, et al. Platelets treated with Helinx technology to inactivate pathogens and contaminating T-cells prevented Transfusion-Associated Graft vs. Host Disease (TA-GVHD): Results of 3 clinical trials.
3. Dupuis K, Alfonso R, Savoor A, et al. Helinx technology inactivates high titers of a variety of emerging blood-borne pathogens in platelets.
4. Ciaravino V, McCullough T. Pharmacokinetic and toxicology assessment of photochemically-treated platelets: No toxicologically relevant effects.

The Network for Advancement of Transfusion Alternatives First North American Symposium (NATA)
June 2003 | San Francisco, California, USA      
[back to top]

1. Sawyer L, Dupuis K, Alfonso R, et al. Helinx technology, used in the INTERCEPT Blood System, inactivates emerging insect-borne pathogens in platelets, plasma, and red blood cell

The 8th Congress of the European Hematology Association (EHA)
June 2003 | Lyon, France     
[back to top]

1. Sawyer L, Dupuis K, Alfonso E, et al. The INTERCEPT Blood System for platelets inactivates high titers of a variety of blood-borne pathogens in platelets.
2. Ciaravino V, McCullough T, Sullivan T. The lack of toxicity in a 3-month dog study administered autologous platelets treated with the INTERCEPT Blood System.

The 8th Annual Intercontinental Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 2003 | Arlington, Virginia, USA      
[back to top]

1. Gao X, Botteman MF, Weissfeld JL, et al. Cost-effectiveness of transfusing platelet components prepared with pathogen inactivation treatment in orthopedic surgery in the United States.

The 2003 Pediatric Academic Societies' Annual Meeting (PAS)
M ay 2003 | Seattle, Washington, USA
[back to top]

1. Strauss R, Eastlund D, Lopez-Plaza I, et al. INTERCEPT Platelets provided effective hemostasis in thrombocytopenic children: Results of the SPRINT trial
   

The American Society for Blood and Marrow Transplantation (ASBMT)
January 2003 | Keystone, Colorado, USA      
[back to top]

1. Lin L, Corash L. Prevention of platelet TA-GVHD by use of INTERCEPT Blood System.